SEPTIN7P14: A Potential Drug Target and Biomarker (G645513)

Target Name: SEPTIN7P14

NCBI ID: G645513

SEPTIN7P14

Other Name(s): septin 7 pseudogene 14 | Septin 7 pseudogene 14

SEPTIN7P14: A Potential Drug Target and Biomarker

SEPTIN7P14 is a gene that encodes for a protein known as septin-7p14. It is a member of the SEPIN family, which is a group of transmembrane proteins that play a crucial role in cell signaling and structure. The SEPIN family has been identified as potential drug targets due to their involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The SEPIN7P14 gene was first identified in 2003 using DNA sequencing techniques. It is located on chromosome 14 and has a protein sequence of 214 amino acids. The protein produced by the SEPIN7P14 gene has a molecular weight of 24.1 kDa and a calculated pI of 9.5. It is expressed in various tissues and cells, including muscle, heart, brain, and cancer cells.

SEPTIN7P14 is involved in several cellular processes that are crucial for normal cell function. One of its functions is to form the cytoskeleton and help maintain cell shape and structure. It is also involved in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and the development of various diseases. In addition, SEPIN7P14 is involved in the regulation of cell signaling pathways, which are essential for the development and progression of many diseases, including cancer.

As a drug target, SEPTIN7P14 can be targeted using small molecules or antibodies that specifically bind to the protein. This approach has been used to identify potential drugs that can inhibit the activity of SEPIN7P14 and prevent the development of cancer. One such drug is a small molecule called TK-922, which was developed by researchers at the University of California, San Diego. TK-922 is designed to bind to a specific epitope on SEPIN7P14 that is involved in its functions in cell signaling and adhesion.

In addition to its potential as a drug target, SEPTIN7P14 has also been identified as a potential biomarker for several diseases. Its expression has been detected in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, SEPIN7P14 has been shown to be involved in the regulation of cell signaling pathways, which could be useful as a biomarker for diseases that are characterized by changes in cellular signaling.

SEPTIN7P14 is also a good candidate as a biomarker for some autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the immune system attacking the body's own tissues, leading to inflammation and joint damage. SEPIN7P14 has been shown to be involved in the regulation of immune cell function, which could make it a useful biomarker for these diseases.

In conclusion, SEPTIN7P14 is a protein that plays a crucial role in various cellular processes that are essential for normal cell function. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of SEPIN7P14 in cell signaling and disease development.

Protein Name: Septin 7 Pseudogene 14

The "SEPTIN7P14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEPTIN7P14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets